Clinical trials: Rituximab, completed
B-Cell Lymphoma
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose…
- Trial name
- NCT00965289
- Testing
- Rituximab
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Nantes University Hospital
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
The purpose of this study is to evaluate the safety, tolerability and clinical activity of RO6870810 in combination with venetoclax and when co-administered with rituximab in participants with relapse/refractory (R/R) diffuse…
- Trial name
- NCT03255096
- Testing
- RO6870810, Venetoclax, Rituximab
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in…
- Trial name
- NCT03003520
- Testing
- Durvalumab, Rituximab, Doxorubicin
- Where
- 20 sites in United States, Austria and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
CLLM1 is a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that compares the efficacy and safety of oral lenalidomide maintenance therapy to that of placebo maintenance therapy in…
- Trial name
- NCT01556776
- Testing
- lenalidomide
- Where
- 2 sites in Germany
- Volunteers
- 89 people
- Sponsor
- German CLL Study Group
Multiple Sclerosis
Czech Pharmaco-epidemiological Study on Disease Modifying Drugs
Multiple sclerosis (MS) is a severe autoimmune disease that affects mainly young individuals. It is estimated that there are 17-20,000 affected persons in the Czech Republic.
- Trial name
- CPE (NCT05762003)
- Testing
- interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
- Where
- Czechia
- Volunteers
- 17,478 people
- Sponsor
- IMPULS Endowment Fund
Diffuse Large B-Cell Lymphoma
Mini-CHOP and Rituximab in Patients Aged Over 80 Years
The purpose of the study is to evaluate efficacy and safety of R-miniCHOP for elderly patients with diffuse large B-Cell lymphoma (DLBC) Lymphoma aged over 80 years by measuring the overall survival.
- Trial name
- NCT01087424
- Testing
- R mini CHOP
- Volunteers
- 150 people
- Sponsor
- Lymphoma Study Association
B-Cell Chronic Lymphocytic Leukemia
Rituximab in Pretreated Elderly or Unfit B-CLL Patients
The study will test the efficacy rituximab in addition to glucocorticoids for the treatment of B-CLL in elderly or unfit patients.
- Trial name
- NCT01576588
- Testing
- Rituximab, Glucocorticoid
- Where
- Lithuania
- Volunteers
- 25 people
- Sponsor
- Prof. Dr. Med. Laimonas Griskevicius
Rheumatoid Arthritis
Treatment of TNFa Naive Patients With Poor Prognosis Rheumatoid Arthritis
The purpose of this study is to determine how well Rituximab works in early stages of disease and the effects it has on an inflamed joint and blood cells.
- Trial name
- NCT00963703
- Testing
- Rituximab
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University of Manitoba
Follicular Lymphoma, Mantle Cell Lymphoma
Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
This is a multicenter, open label, single arm, phase I/II study. There will be no placebo usage within this trial. Phase I: Primary: To establish a maximum tolerated dose of the addition of Temsirolimus to a regimen of…
- Trial name
- BERT (NCT01078142)
- Testing
- Temsirolimus, Rituximab, Bendamustin
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- Georg Hess, MD
Lymphoma
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01216683
- Testing
- rituximab, Bendamustin, bortezomib
- Where
- 227 sites in United States
- Volunteers
- 289 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Hodgkin's Lymphoma
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Primary Objective: To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when administered in combination with CHOP + Rituximab to patients with previously untreated diffuse large B cell or mantle cell…
- Trial name
- NCT00151320
- Testing
- Bortezomib, CHOP, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- Weill Medical College of Cornell University
Membranous Nephropathy
Rituximab in Membranous Nephropathy
Membranous glomerulopathy (MN) is a common immune-mediated glomerular disease and the leading cause of nephrotic syndrome in Caucasian adults.
- Trial name
- NCT00425217
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab Secondary Objectives: To determine…
- Conditions
- Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01410513
- Testing
- SAR245409
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sanofi
Lupus Erythematosus, Systemic
Synergetic B-cell Immodulation in SLE
The present study investigates the potential of a new therapeutic approach in lupus nephritis combining rituximab (anti-CD20) and belimumab (anti-BAFF).
- Trial name
- SYNBIoSe (NCT02284984)
- Testing
- Rituximab with belimumab
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Leiden University Medical Center
Polymyalgia Rheumatica
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed
Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing…
- Trial name
- REDUCE-PMR-1 (NCT05533125)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 114 people
- Sponsor
- Sint Maartenskliniek
Lymphoma
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01131208
- Testing
- gene expression analysis, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non Hodgkin's Follicular Lymphoma
VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma
The aim of this study was to evaluate the efficacy and safety of the combination of Velcade and Rituximab in patients with relapsed Non Hodgkin's Follicular Lymphoma.
- Trial name
- NCT01830465
- Testing
- Bortezomib (VELCADE), Rituximab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Italiano Studio Linfomi
Kidney Transplantation
Rituximab for Prevention of Rejection After Renal Transplantation
Our standard immunosuppressive treatment after renal transplantation is a combination of tacrolimus, mycophenolate mofetil, and prednisolone.
- Trial name
- NCT00565331
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 280 people
- Sponsor
- Radboud University Medical Center
Lymphoma, Leukemia
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of…
- Trial name
- NCT00048737
- Testing
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Waldenstrom's Macroglobulinaemia
Randomised Trial in Waldenstrom's Macroglobulinaemia
The purpose of this trial is to assess tolerability and efficacy of the Bortezomib, Cyclophosphamide and Rituximab combination as initial therapy for previously untreated patients with symptomatic Waldenstrom's macroglobulinaemia.
- Trial name
- R2W (NCT01592981)
- Testing
- Bortezomib, Cyclophosphamide, Rituximab
- Where
- 30 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.